Retrophin Inc (RTRX) : Perceptive Advisors scooped up 280,000 additional shares in Retrophin Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 3,279,380 shares of Retrophin Inc which is valued at $68,834,186.Retrophin Inc makes up approximately 4.46% of Perceptive Advisors’s portfolio.
Other Hedge Funds, Including , Senzar Asset Management boosted its stake in RTRX in the latest quarter, The investment management firm added 141,300 additional shares and now holds a total of 470,789 shares of Retrophin Inc which is valued at $9,881,861. Retrophin Inc makes up approx 2.56% of Senzar Asset Management’s portfolio.Blackrock Japan Ltd boosted its stake in RTRX in the latest quarter, The investment management firm added 175 additional shares and now holds a total of 618 shares of Retrophin Inc which is valued at $11,322.Blackrock Group Ltd boosted its stake in RTRX in the latest quarter, The investment management firm added 1,219 additional shares and now holds a total of 15,448 shares of Retrophin Inc which is valued at $283,007. American Century Companies Inc added RTRX to its portfolio by purchasing 98,096 company shares during the most recent quarter which is valued at $1,805,947.
Retrophin Inc closed down -1.31 points or -6.12% at $20.08 with 6,21,016 shares getting traded on Monday. Post opening the session at $21.94, the shares hit an intraday low of $19.56 and an intraday high of $21.94 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Retrophin Inc reported $-0.09 EPS for the quarter, missing the analyst consensus estimate by $ -0.15 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $0.06. The company had revenue of $33.95 million for the quarter, compared to analysts expectations of $34.78 million. The company’s revenue was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.
Retrophin Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery acquisition development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound Sparsentan for FSGS. The Company’s products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034 which are in pre-clinical stage.